Skip to main content
SleepCited

Restless legs syndrome. Pathophysiology, diagnosis and treatment.

Federico Castillo-Álvarez, María Eugenia Marzo-Sola
Review Medicina clinica 2025 11 citations
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D39209614'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Type d'étude
Review
Population
None
Intervention
Restless legs syndrome. Pathophysiology, diagnosis and treatment. None
Comparateur
None
Critère de jugement principal
None
Direction de l'effet
Mixed
Risque de biais
Unclear

Abstract

Restless legs syndrome is the most prevalent sleep-related movement disorder, affecting 5-10% of the population, characterized by an urge to move that appears during rest or is exacerbated by rest, primarily in the lower extremities, that occurs in the evening or night and that disappears during movement or is improved by movement. Restless legs syndrome significantly impacts sleep, mood, and quality of life. Its pathophysiology involves a complex interplay of genetic and environmental factors, as well as comorbidities, leading to alterations in brain iron resulting in dysfunction in dopaminergic, adenosine, and glutamatergic pathways. Treatment typically includes iron supplementation and symptomatic therapy, traditionally utilizing dopamine agonists. However, their long-term use may exacerbate symptoms, relegating them to second-line treatment after ligands α2δ of calcium channels.

En bref

Treatment typically includes iron supplementation and symptomatic therapy, traditionally utilizing dopamine agonists, however, their long-term use may exacerbate symptoms, relegating them to second-line treatment after ligands α2δ of calcium channels.

Used In Evidence Reviews

Similar Papers